Recursion prices $200M stock offering at $3.25 per share
Summary
Recursion Pharmaceuticals priced a public offering of 61.54 million Class A shares at $3.25 each. The company expects to raise about $200 million in gross proceeds before fees and expenses. Recursion is selling all of the shares itself, and the offering is scheduled to close shortly after pricing, subject to customary conditions. Institutional investors and healthcare-focused funds are participating, while major banks are serving as bookrunning managers.
Funding
Amount
$200.0M
Total raised
Date
October 15, 2026
Announcement date
Investors
Recursion Pharmaceuticals, Invus, Leerink Swann & Company, Goldman Sachs, Evercore, Morgan Stanley Principal Investments, Janus Henderson Investors, Driehaus Capital Management, Needham & Company
Lead investors
Company
https://recursion.com
Funded company
AskAI Classifications
Sectors
Life Sciences and Pharmaceutical
Life Sciences Analytics
Functions
Developer and IT Infrastructure
Business Intelligence and Analytics
Development Platforms
Linked Companies
Recursion Pharmaceuticals, Inc.
$50M to $100M